Colon Cancer Survival Rates by Stage

Population statistics cannot predict what will happen to one person. But they do show precisely how much the stage at diagnosis matters.

Five-year relative survival by stage

The most commonly cited measure is five-year relative survival: the percentage of people still alive five years after diagnosis, compared with people of the same age who do not have cancer. For colorectal cancer, the widely published figures from the National Cancer Institute's SEER program are approximately:

Approximate five-year relative survival for colorectal cancer, by stage at diagnosis
Stage at diagnosis5-year relative survival What it means
Localized (confined to the colon or rectum)about 91% The cancer has not spread beyond the wall of the colon. This is where screening and early diagnosis place a patient.
Regional (spread to nearby lymph nodes)about 73% The cancer has reached regional lymph nodes but not distant organs.
Distant (metastasized)about 13% The cancer has spread to distant organs such as the liver or lungs.
All stages combinedabout 53% The average across every stage at diagnosis.

Verify current figures

These percentages are rounded, are drawn from population registry data, and are updated periodically as treatment improves. For the current published numbers, see the National Cancer Institute and the American Cancer Society. See our resources page for the full list.

What these numbers do not mean

Survival statistics are averages across large populations. They cannot tell you what will happen to any individual. Two patients at the same stage can have very different outcomes depending on tumor biology, grade, response to treatment, age and general health.

Equally important: these figures describe patients diagnosed at various times in the past. Many were diagnosed years before the most current treatments became available, so the outlook for a patient diagnosed today may be better than the table suggests.

What the numbers do show: the cost of delay

Read the table again as a description of movement. A patient whose cancer is found while localized sits in a group with a very high survival rate. A patient whose diagnosis is delayed until the cancer has reached lymph nodes moves to a substantially lower rate. A patient whose diagnosis is delayed until the cancer has metastasized moves to a dramatically lower one.

That movement is not an abstraction. It is the measurable harm at the center of a delayed diagnosis case: a patient who could have been in the first row was instead diagnosed in the second or third, because a test was not ordered, a result was not followed up, or a symptom was not investigated.

How this connects to a legal claim

In a malpractice case, the question is usually not whether the patient would certainly have been cured, but whether the delay deprived them of a substantial chance of a better outcome — a concept often described as loss of chance. Survival statistics by stage are one of the tools used to measure that loss. See how a malpractice claim works and failure to diagnose.

Has your colon cancer diagnosis been delayed?

Every state limits how long you have to file. A free, confidential review costs you nothing and tells you where you stand.